Teijin Pharma Ltd. has entered into an exclusive global licensing agreement with Bioprojet under which Teijin Pharma grants Bioprojet Pharma SAS exclusive worldwide rights to research, develop, manufacture and commercialize an investigational candidate for narcolepsy.

NLS Pharmaceutics Ltd. has entered into an exclusive worldwide license agreement with Aexon Labs Inc. granting NLS the opportunity to acquire global development and commercialization rights to Aexon’s next-generation nonsulfonamide dual orexin receptor agonists platform.

NLS Pharmaceutics Ltd. has entered into an exclusive worldwide option agreement with Aexon Labs Inc.

Researchers from Centessa Pharmaceuticals plc presented the preclinical characterization of ORX-750, a novel selective orexin receptor 2 (OX2R) agonist aimed to be used for the treatment of narcolepsy.

Despite its promising therapeutic efficacy in patients with narcolepsy type 1, the previously reported orally available orexin OX2 receptor (OX2R) agonist TAK-994 has also demonstrated off-target liver toxicity. Now, researchers from Takeda Pharmaceutical Co. Ltd. have reported the discovery and early evaluation of a new OX2R agonist, TAK-861, being developed for the treatment of narcolepsy and other hypersomnia disorders.